株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

幹細胞:世界の幹細胞移植・臍帯血バンク・薬剤開発市場

Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer's, Diabetes, Arthritis and Other Diseases)

発行 Kalorama Information 商品コード 227816
出版日 ページ情報 英文 160 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
幹細胞:世界の幹細胞移植・臍帯血バンク・薬剤開発市場 Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer's, Diabetes, Arthritis and Other Diseases)
出版日: 2012年01月01日 ページ情報: 英文 160 Pages
概要

当レポートでは、幹細胞移植・臍帯血(さい帯血)バンク・薬剤開発市場の現状と見通しについて調査分析し、幹細胞の種類と概要、幹細胞の採取と用途、現在幹細胞治療が行われている疾患区分と開発中の疾患疾患区分、幹細胞治療・臍帯血バンクの収益実績・予測(〜2020年:シナリオ別)、幹細胞ベースの薬剤開発における技術料の実績・予測(〜2020年:シナリオ別)、倫理的問題などの各種課題などをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 医療における幹細胞の確実性
  • 幹細胞のタイプ
  • 幹細胞の採取
  • 胚性幹細胞
  • 治療目的のクローニング
  • 未受精卵
  • 成体幹細胞
  • 白血球アフェレーシス
  • 末梢血
  • 臍帯血幹細胞
  • 移植アプローチ
  • 癌性幹細胞
  • その他の有害な幹細胞
  • 薬剤開発における幹細胞
  • 幹細胞治療
  • 幹細胞を標的とする医薬品
  • 幹細胞からの組織作成

第3章 現在の幹細胞治療

  • 白血病
  • 遺伝子治療
  • 多発性骨髄腫
  • 非ホジキンスリンパ腫
  • 非癌性疾患
  • 再生不良性貧血
  • 免疫不全
  • 狼瘡
  • 鎌状赤血球症
  • その他の症状

第4章 幹細胞治療の開発

  • アルツハイマー病
  • 関節炎
  • 膀胱疾患
  • 火傷
  • 心血管疾患
  • 重症虚血肢
  • 糖尿病
  • 食道疾患
  • 失禁
  • 不妊症
  • 消化管疾患
  • 肝機能不全
  • 肺疾患
  • 多発性硬化症
  • 整形外科
  • 骨粗鬆症
  • パーキンソン病
  • 鎌状赤血球症
  • 歯疾患
  • しわ/皮膚老化

第5章 幹細胞市場の予測

  • ベストケース
  • もっとも起こりうるケース
  • ワーストケース

第6章 幹細胞研究における課題

  • 倫理的問題
  • 米国:州および国によるイニシアチブ
  • 幹細胞の特許
  • その他の医療関連法規制

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI6490034

Abstract

There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government's policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

  • Stem Cells in Drug Development
  • Stem Cells in Cord Blood Banking
  • Stem Cell Therapeutics

Stem cell therapeutics potentials are provided, broken down by disease:

  • Cardiovascular disease
  • Lung disease
  • Tooth disease
  • Arthritis
  • Wrinkles/aging skin
  • Incontinence
  • Osteoporosis
  • Diabetes
  • Cancer
  • Bladder disease
  • Infertility
  • Orthopedics
  • Alzheimer's disease
  • Burns (severe)
  • Lupus
  • Parkinson's disease
  • Liver failure
  • Multiple sclerosis
  • Critical limb ischemia
  • Intestinal disease
  • Sickle cell disease
  • Multiple myeloma
  • NH Lymphoma
  • Leukemia

The following trends are discussed in this report:

  • Ethical Questions
  • U.S. - State and Federal Initiatives
  • Research Funding
  • Cord Blood Initiatives
  • International Initiatives
  • Stem Cell Patents
  • Other Healthcare Regulations

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Scope and Methodolgy
  • Introduction
  • Current Stem Cell Therapies
  • Developmental Stem Cell Therapies
  • Issues In Stem Cell Research
  • Stem Cell Forecasts

CHAPTER TWO: INTRODUCTION

  • The Promise of Stem Cells In Medical Treatment
  • Types of Stem Cells
    • Embryonic Stem Cells
    • Adult Stem Cells
    • Cord Blood Stem Cells
  • Stem Cell Harvesting
  • Embryonic Stem Cells
  • Therapeutic Cloning
  • Unfertilized Eggs
  • Adult Stem Cells
  • Leukapheresis
  • Peripheral Blood
  • Cord Blood Stem Cells
  • Transplantation Approaches
    • Autologous Transplantation
    • Allogenic Transplantation
    • Transplantation Procedures
  • Cancerous Stem Cells
  • Other Harmful Stem Cells
  • Stem Cells in Drug Development
  • Stem Cell Therapeutics
  • Stem Cells Targeting Drugs
  • Stem Cell Generated Organs

CHAPTER THREE: CURRENT STEM CELL THERAPIES

  • Cancer
  • Leukemia
  • Gene Therapy
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Non Cancerous Diseases
  • Aplastic anemia
  • Immunodeficiency
  • Lupus
  • Sickle Cell Disease
  • Other Conditions

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

  • Alzheimer's Disease
  • Arthritis
  • Bladder Disease
  • Burns
  • Cancer
  • Cardiovascular Conditions
  • Critical Limb Ischemia
  • Diabestes
  • Esophagal Disease
  • Incontinence
  • Infertility
  • Intestinal Disease
  • Liver Failure
  • Lung Disease
  • Multiple Sclerosis
  • Orthopedics
  • Osteoporosis
  • Parkinson's Disease
  • Sickle Cell Disease
  • Tooth Disease
  • Wrinkles/Aging Skin

CHAPTER FIVE: STEM CELL FORECASTS

  • Best Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development
  • Most Likely Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development
  • Worst Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

  • Ethical Questions
  • U.S. - State and Federal Initiatives
    • Research Funding
    • Federal Funding
    • State Funding
    • Cord Blood Initiatives
    • International Initiatives
  • Stem Cell Patents
  • Other Healthcare Regulations

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 - 2020
  • Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 - 2020
  • Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 - 2020
  • Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 - 2020
  • Figure 1-1 Total Market for Stem Cells - Most Likely Case in $ Millions, 2010 - 2020

CHAPTER TWO: INTRODUCTION

  • Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

CHAPTER THREE: CURRENT STEM CELL THERAPIES

  • Table 3-1 Types of Leukemia, 2011

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

  • Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011
  • Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
  • Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020
  • Table 4-4 Features and Types of Urinary Incontinence, 2011
  • Table 4-5 Types and Causes of Male Infertility, 2011
  • Table 4-6 Common Diseases of the Lungs, 2011

CHAPTER FIVE: STEM CELL FORECASTS

  • Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011
  • Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 - 2020
  • Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020
  • Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
  • Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 - 2020
  • Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020
  • Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
  • Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020
  • Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020
  • Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

  • Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in $ Million
  • Table 6-2 U.S. State Embryonic & Fetal Research Laws
  • Table 6-3 Positions on Human ES Cell Research by Country, 2011
  • Table 6-4 EU Laws on hESC Research by Country
Back to Top